Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs
Pharma juggernauts Pfizer and Novo Nordisk are struggling in the obesity drug race.The two companies are searching for their next moneymaker, and that search recently spun out into a ferocious, multibillion-dollar battle for control of biotech start-up Metsera. The FT’s US deals and activism correspondent Oliver…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from The Story of Money
See all episodes →
The French Revolution's disastrous money experiment - Part 2
The French Revolution's disastrous money experiment - Part 1
How the US financed World War I using Charlie Chaplin and Girl Scouts
Similar episodes from other shows
More like The Story of Money →
Big deals in Big Pharma
Pfizer plays hardball in weight-loss drug fight
Novo Nordisk's CEO Has a Comeback Plan
What’s News in Earnings: Who Is Winning the Obesity-Drug Arms Race?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.